SUPPORTIVE CARE OF CHILDREN WITH CANCER: PREVENTION AND TREATMENT OF CHEMOTHERAPY-INDUCED LIVER TOXICITY (MODIFICATION OF CHEMOTHERAPEUTIC AGENTS THAT PRODUCE LIVER TOXICITY)
Wednesday, July 27th, 2011A. L-AsparaginaseL-Asparaginase can result in fatty metamorphosis.Liver enzyme abnormalities may be reversible while continuing therapy.Stop therapy for grade 3 or greater liver toxicity; resume at grade 2.B. 6-Mercaptopurine and 6-Thioguanine6-Mercaptopurine (6-MP) or 6-thioguanine (6-TG) can resultin cholestasis.Stop if toxicity is grade 3 or greater.Rule out viral hepatitis, Gilbert disease, or tumor effect.If drugs are the cause of liver toxicity, restart at 50% dose when the toxicity decreases to grade 2.If grade 3 or greater toxicity persists, it may be necessary to perform a liver biopsy to determine the histologic extent of the disease and whether 6-MP/6-TG can be restarted.C. MethotrexateMethotrexate can result in fibrosis and cirrhosis.1. There does not appear to be a need to modify the dosage in patients with preexisting liver damage, other than to consider whether the patient can tolerate the potential additional hepatic dysfunction induced by methotrexate.Stop if toxicity is grade 3 or greater.Rule out viral hepatitis, Gilbert disease, or drug effect.If the drug is the cause of liver toxicity, restart at 50% dose when toxicity decreases to grade 2.If grade 3 or greater toxicity persists, it may be necessary to perform a liver biopsy to determine the histologic extent of the disease and whether methotrexate can be restarted.D. Carmustine and lomustineBCNU and CCNU can result in increased liver enzymes.Stop if toxicity is grade 3 or greater.Rule out viral hepatitis or tumor effect.If drugs are the cause, restart at 50% dose when the toxicity decreases to grade 1.If grade 3 or greater toxicity persists, it may be necessary to perform a liver biopsy to determine the histologic extent of the disease and whether BCNU/CCNU can be restarted.*37\168\2*